Ljubljana 2014 Registration Programme Satellite Meetings Exhibition Hotel Information Virtual Exhibition Visa Information
Back to Freepaper Session

Intrastromal corneal ring segment implantation (355

Session Details

Session Title: Refractive

Session Date/Time: Sunday 16/02/2014 | 08:30-11:00

Paper Time: 09:56

Venue: Kosovel Hall (Level -2)

First Author: : Seyed aliasgharMosavi IRAN

Co Author(s): :    Khosrow Jadidi   Mostafa Naderi   Farhad Nejat   Leila Janani     

Abstract Details

Purpose:

To report the results of intrastromal corneal ring segment [ICRS] (355º KeraRing; Mediphacos, Belo Hori- zonte, Brazil) implantation in keratoconic patients.

Setting:

Ophthalmology Department, Bina Eye Hospital Research Center, Tehran, Iran

Methods:

In this prospective study,Ten keratoconic patients (10 eyes) who underwent ICRS insertion (355º KeraRing) and completed at least 3 months of follow-up were included in this study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), refraction, topographic findings, and adverse events were assessed.

Results:

No intraoperative and postoperative complications were demonstrated in this series of patients. At the last postoperative examination, there was a statistically significant reduction in the spherical equivalent refractive error compared with that observed at the examination before implantation (mean ±standard deviation, -2.7±1.8 diopters [D; range, -1.5 to -6.5 D] to -0.6±0.8 diopters [D;range, -1.5 to 0.5 D]; P = 0.027). The The mean preoperative UCVA (logMAR) before implantation was 0.74±0.25 (range, 0.5 to 1.0), whereas at the last follow-up examination, had a UCVA of 0.48±0.16 (range, 0.3 to 0.7). The mean preoperative BSCVA (logMAR) before implantation was 0.33±0.18(range 0.22 to 0.7, whereas at the last follow-up examination had a BSCVA of 0.24±0.10 (range 0.15 to 0.4). No late postoperative complications were observed during the follow-up period.

Conclusions:

ICRS (355º KeraRing) implantation is a minimally invasive procedure for improving visual acuity (both UCVA and BSCVA) in keratoconic patients. FINANCIAL INTEREST: NONE